- Home
- PODD vs SNN Comparison
PODD vs SNN Comparison
Compare PODD & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PODD | SNN |
|---|---|---|
| Founded | 2000 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 12.3B |
| IPO Year | 2007 | 2002 |
Fundamental Metrics
Financial Performance| Metric | PODD | SNN |
|---|---|---|
| Price | $141.64 | $29.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 26 | 6 |
| Target Price | ★ $167.17 | $32.32 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 11-04-2026 | 08-04-2026 |
| Dividend Yield | N/A | ★ 2.63% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.67 | N/A |
| Revenue | ★ $2,708,100,000.00 | N/A |
| Revenue This Year | $21.37 | $4.89 |
| Revenue Next Year | $13.57 | $5.25 |
| P/E Ratio | ★ $51.96 | $64.97 |
| Revenue Growth | ★ 30.73 | N/A |
| 52 Week Low | $126.40 | $26.30 |
| 52 Week High | $354.88 | $37.51 |
Technical Indicators
Market Signals| Indicator | PODD | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 66.47 |
| Support Level | $139.67 | $28.87 |
| Resistance Level | $143.45 | $29.69 |
| Average True Range (ATR) | 3.53 | 0.41 |
| MACD | 1.15 | 0.33 |
| Stochastic Oscillator | 86.30 | 87.68 |
Price Performance
Historical ComparisonAbout PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.